Will AI Be The X-Factor In Apple’s Next iPhone?
AI is anticipated to be a major feature in the devices launching this fall, likely under the iPhone 16 label.
What’s Going On With Plug Power Shares Today?
Plug Power emphasizes short-term priorities in annual meeting; government watchdog examines recent $1.66B financing amid concerns.
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential
New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and the concentrated risks associated with these investments.
AbbVie’s Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability
Humira maintains over 80% of its market share despite facing nine biosimilar rivals, raising concerns about the future of the biosimilar market and prompting calls for regulatory reform to enhance patient access and incentivize development.
Meta Introduces AI-Powered Ad Targeting On WhatsApp: Report
Meta Platforms Inc. has launched its first AI-powered ad targeting program for businesses on WhatsApp, marking a significant shift for the messaging service known for its privacy.
Japanese Mega Banks Plan $8.5B Toyota Stake Sale: Report
Mitsubishi UFJ Financial Group Inc. and Sumitomo Mitsui Financial Group Inc. are set to divest ¥1.32 trillion ($8.5 billion) in Toyota Motor Corp. shares. This strategic move aligns with Japan's push to reduce cross-held shares.
Ozempic, Wegovy Create Domino Effect As New Products Emerge Across Industries To Capture New Consumer Habits
Companies from food and beverage to fitness are adapting to the increased demand for these drugs, hoping to capitalize on shifting consumer habits
What’s Going On With NIO Shares Friday?
NIO has entered into a charging network-sharing partnership with GAC, marking the first significant progress since their collaboration agreement a month prior. Yesterday, NIO reported its disappointing Q1 2024 revenue results.
FDA Approves Geron’s First Commercial Drug, Competes With Bristol Myers Squibb’s Blood Cancer Drug
FDA approves Geron's Rytelo (imetelstat) for adults with low-to intermediate-1 risk myelodysplastic syndromes and transfusion-dependent anemia Geron's first commercial treatment targets a market potential of $1.2 billion.
Airbus Revamps Toulouse Facility To Boost A320neo Production: Report
Airbus SE is reportedly building a new assembly line for its A320neo-family aircraft in Toulouse to replace an older, less efficient one, enhancing production efficiency. The project will modernize and speed up production to meet increasing demand amid supply constraints.